2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
التفاصيل البيبلوغرافية
العنوان:
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Cardiovascular Centre (CVC), Surgical clinical sciences, Cardiac Surgery
المصدر:
European Heart Journal European Heart Journal, Oxford University Press (OUP): Policy B, 2020, ⟨10.1093/eurheartj/ehaa612⟩ Российский кардиологический журнал, Vol 26, Iss 9 (2021) European Heart Journal, 42(5), 373-498. Oxford University Press European Heart Journal, 42(5), 373-498. OXFORD UNIV PRESS
Supplementary Table 9, column 'Edoxaban', row 'eGFR category', '95 mL/min' (page 15). The cell should be coloured green instead of yellow. It should also read "60 mg"instead of "60 mg (use with caution in 'supranormal' renal function)."In the above-indicated cell, a footnote has also been added to state: "Edoxaban should be used in patients with high creatinine clearance only after a careful evaluation of the individual thromboembolic and bleeding risk."Supplementary Table 9, column 'Edoxaban', row 'Dose reduction in selected patients' (page 16). The cell should read "Edoxaban 60 mg reduced to 30 mg once daily if any of the following: creatinine clearance 15-50 mL/min, body weight
